ClearView Convos: Episode 1

Sam Ulin moderates a discussion with Pricing & Market Access Partners Mike Rizzo and Rishi Dalsania discussing the implications of a recent executive order on most-favored-nation pricing for the US market. The order aims to normalize pricing across major markets, though the specifics and consequences remain unclear. The group explored potential impacts on innovation and pricing strategies, acknowledging the uncertainty surrounding the order’s implementation and long-term effects on the biopharmaceutical industry.

Recorded May 16, 2025